Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma: a Prospective Non-randomized, Multicenter Phase II Study

NCT00623402 is registered in ClinicalTrials.gov with University Hospital Schleswig-Holstein as lead sponsor.

NCT NCT00623402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00623402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma: a Prospective Non-randomized, Multicenter Phase II Study
Lead sponsor
University Hospital Schleswig-Holstein
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2008
Completion date
Not reported
Enrollment
55 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma